D. Lorne Tyrrell
2015 Canada Council Killam Prize Laureate in Health Sciences – University of Alberta
Virologist Lorne Tyrrell participated in the discovery of several potent anti-virals against Hepatitis B (HBV), which notably led to a major collaboration with GlaxoSmithKline and the most prestigious award in the field of Canadian pharmaceutical research and innovation, the Prix Galien Canada. The drug Lamivudine is marketed under the name Heptovir and licensed worldwide as the first oral anti-viral for the treatment of HBV infections. He is currently working on the viral and host genetic factors that lead to chronic HBV and Hepatitis C (HCV), and on an HCV vaccine.
The Killam Prizes
Every year the Killam Program offers five awards of $100,000 each to outstanding Canadian scholars working in the humanities, social sciences, natural sciences, health sciences and engineering in recognation of outstanding career achievements. These awards are among Canada’s most distinguished research awards. They are made possible through the Killam Trusts by a bequest of Mrs. Dorothy J. Killam, and a gift she made before her death in 1965. Recipients are chosen by a committee of 15 eminent Canadian scholars appointed by the Canada Council.
To learn more about Dr. Tyrrell's research, please visit his website or watch the video below: